表紙:核酸分離および精製の世界市場 - 成長、動向、予測(2022年~2027年)
市場調査レポート
商品コード
661017

核酸分離および精製の世界市場 - 成長、動向、予測(2022年~2027年)

Nucleic Acid Isolation and Purification Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 112 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
核酸分離および精製の世界市場 - 成長、動向、予測(2022年~2027年)
出版日: 2022年01月17日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 112 Pages
納期: 2~3営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の核酸分離および精製市場の成長は、急速な技術進歩、診断分野における核酸試験の多様な用途、バイオテクノロジーおよびヘルスケアにおける研究開発資金の増加などによって促進されています。

当レポートでは、世界の核酸分離および精製市場を調査し、市場の概要、技術・製品・用途・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場の成長要因
    • 急速な技術進歩
    • 診断分野における核酸検査の多様な用途
    • バイオテクノロジーとヘルスケアにおける研究開発資金の増加
  • 市場の阻害要因
    • 新興市場での浸透の低さ
    • 自動装置のコストの上昇
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • 技術別
    • カラム精製
    • 磁気ビーズベース精製
    • 試薬ベース精製
  • 製品別
    • キット・試薬
    • 装置
    • その他
  • 用途別
    • トータルRNA分離・精製
    • mRNA分離・精製
    • マイクロRNA分離・精製
    • プラスミドDNA分離・精製
    • ゲノムDNA分離・精製
    • 血液DNA分離・精製
    • PCRクリーンアップ
    • その他
  • エンドユーザー別
    • 病院
    • 学術機関
    • 製薬・バイオテクノロジー企業
    • 医薬品開発受託機関(CRO)
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Agilent Technologies
    • Bio-Rad Laboratories Inc.
    • BioTek Instruments Inc.
    • BioVision Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd
    • GE Healthcare
    • Merck KGaA (Sigma-Aldrich Corporation)
    • Promega Corporation
    • Qiagen NV

第7章 市場機会および将来動向

目次
Product Code: 50452

The Nucleic Acid Isolation and Purification Market is expected to register a CAGR of 6.6% during the forecast period. growth of the nucleic acid isolation and purification market is due to the rapid technological advancements, wide-range applications of nucleic acid testing in diagnostics, and rise in the R&D funding in biotechnology and healthcare.

Key Highlights

  • Nucleic acid has many diagnostic applications in tests of many diseases, such as STDs, congenital anomalies, cancer, etc.
  • According to the US Department of Health & Human Services, there were approximately 36.7 million people worldwide living with HIV/AIDS as of 2016. Of these, 2.1 million were children (above 15 years old). The WHO stated that more than 1 million sexually transmitted infections are acquired every day worldwide and 500 million people are estimated to have genital infection with herpes simplex virus (HSV), along with 290 million women who have a human papillomavirus (HPV) infection. Therefore, all STDs can be diagnosed through nucleic acid isolation and identification procedures, and this signifies that the market studied is expected to increase globally.
  • The current market is also growing, due to rapid technological advancements, like polymerase chain reaction (the original nucleic acid amplification technique), which transformed the approach of the clinical microbiologists in viewing and using nucleic acid techniques in clinical settings.

Key Market Trends

The Equipment Segment is Expected to Hold a Major Market Share in the Nucleic Acid Isolation and Purification Market

  • The equipment segment of the market studied is growing at a good pace. There are significant advancements found in the field of molecular diagnostics that have facilitated rapid and continued advancements in nucleic acid isolation and purification technologies, driven by the new knowledge provided by the mapping of genetic risk factors behind many diseases, where lifestyle has an important role to play.
  • According to the World Health Organization (WHO) 2020, the alpha and beta thalassaemias are the most common inherited single-gene disorders in the world. The burden of thalassaemias in many regions of the world represents a major public health concern. For example in Iran, it was estimated that each year about 8,000 pregnancies are at risk of this disorder. Moreover, In addition, it was estimated that the incidence of genetic disorder Down syndrome was between 1 in 1,000 to 1 in 1,100 live births worldwide.
  • Thus, the high incidence of genetic disorders along with growth in laboratory automation and decreasing changeability may lead to the growth of the equipment segment of the market studied.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

  • North America is expected to hold a major market share in the nucleic acid isolation and purification market due to the very high use of downstream processes in the country. The growth of the market is also attributed due to the rapid technological advances, wide-range applications of nucleic acid testing in diagnostics boosting the market, rise in the R&D funding in biotechnology and healthcare.
  • According to the Centers for Disease Control and Prevention (CDC), in the United States Hemophilia A affects 1 in 5,000 male births. Each year approximately 400 babies are born with haemophilia A.
  • Furthermore, the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Nucleic Acid Isolation and Purification Market is fragmented competitive and consists of several major players. Some of the recent market trends in the global nucleic acid isolation and purification market are new product development, mergers and acquisition, and partnerships. Agilent Technologies, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, GE Healthcare, Promega Corporation, Qiagen NV, and Thermo Fisher Scientific Inc. are some of the major players in the nucleic acid isolation and purification market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rapid Technological Advancements Boosting the Market Growth
    • 4.2.2 Wide-range Applications of Nucleic Acid Testing in Diagnostics Boosting the Market
    • 4.2.3 Rise in the R&D Funding in Biotechnology and Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Low Penetration in the Emerging Markets
    • 4.3.2 Increasing Cost of Automated Instruments
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 Column-based Purification
    • 5.1.2 Magnetic Bead-based Purification
    • 5.1.3 Reagent-based Purification
  • 5.2 By Product
    • 5.2.1 Kits and Reagents
    • 5.2.2 Equipment
    • 5.2.3 Other Products
  • 5.3 By Application
    • 5.3.1 Total RNA Isolation and Purification
    • 5.3.2 mRNA Isolation and Purification
    • 5.3.3 microRNA Isolation and Purification
    • 5.3.4 Plasmid DNA Isolation and Purification
    • 5.3.5 Genomic DNA Isolation and Purification
    • 5.3.6 Blood DNA Isolation and Purification
    • 5.3.7 PCR Clean-up
    • 5.3.8 Other Nucleic Acid Isolation and Purification Applications
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Academic and Research Institutes
    • 5.4.3 Pharmaceutical/Biotechnology Industry
    • 5.4.4 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 Bio-Rad Laboratories Inc.
    • 6.1.3 Thermo Fisher Scientific
    • 6.1.4 BioVision Inc.
    • 6.1.5 Danaher Corporation
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 GE Healthcare
    • 6.1.8 Merck KGaA (Sigma-Aldrich Corporation)
    • 6.1.9 Promega Corporation
    • 6.1.10 Qiagen NV

7 MARKET OPPORTUNITIES AND FUTURE TRENDS